Insulet (NASDAQ:PODD) Raised to "Outperform" at Wolfe Research

Insulet (NASDAQ:PODD - Get Free Report) was upgraded by Wolfe Research from a "peer perform" rating to an "outperform" rating in a report released on Tuesday, Marketbeat Ratings reports. The firm presently has a $350.00 target price on the medical instruments supplier's stock. Wolfe Research's price target would indicate a potential upside of 7.78% from the stock's previous close.

A number of other equities research analysts have also recently weighed in on PODD. Raymond James restated an "outperform" rating and issued a $328.00 price target (up previously from $294.00) on shares of Insulet in a research note on Friday, February 21st. StockNews.com cut Insulet from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Oppenheimer increased their price target on Insulet from $312.00 to $324.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They issued an "outperform" rating and a $340.00 price target on the stock. Finally, Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, Insulet currently has an average rating of "Moderate Buy" and an average target price of $306.53.

Insulet Stock Up 0.8%

NASDAQ:PODD traded up $2.73 during trading hours on Tuesday, reaching $324.75. 836,387 shares of the stock were exchanged, compared to its average volume of 706,773. Insulet has a twelve month low of $170.67 and a twelve month high of $326.10. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a 50 day moving average of $262.55 and a 200 day moving average of $265.81. The stock has a market cap of $22.85 billion, a PE ratio of 56.09, a PEG ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, beating the consensus estimate of $0.81 by $0.21. The company had revenue of $569.00 million during the quarter, compared to the consensus estimate of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm's revenue for the quarter was up 28.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.73 EPS. On average, equities analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now directly owns 3,231 shares of the company's stock, valued at approximately $888,525. This represents a 36.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP John W. Kapples sold 5,278 shares of the firm's stock in a transaction dated Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares in the company, valued at $7,382,134.60. This trade represents a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Institutional Trading of Insulet

Several large investors have recently bought and sold shares of PODD. Principal Financial Group Inc. boosted its stake in Insulet by 4.0% in the third quarter. Principal Financial Group Inc. now owns 86,210 shares of the medical instruments supplier's stock valued at $20,065,000 after buying an additional 3,355 shares in the last quarter. Czech National Bank boosted its stake in Insulet by 6.5% in the fourth quarter. Czech National Bank now owns 15,209 shares of the medical instruments supplier's stock valued at $3,971,000 after buying an additional 926 shares in the last quarter. CHICAGO TRUST Co NA acquired a new stake in Insulet in the fourth quarter valued at about $294,000. Cooper Financial Group boosted its stake in Insulet by 14.2% in the fourth quarter. Cooper Financial Group now owns 1,021 shares of the medical instruments supplier's stock valued at $267,000 after buying an additional 127 shares in the last quarter. Finally, Ayrshire Capital Management LLC boosted its stake in Insulet by 34.6% in the fourth quarter. Ayrshire Capital Management LLC now owns 22,988 shares of the medical instruments supplier's stock valued at $6,001,000 after buying an additional 5,911 shares in the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.